Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1684)	7/13/2006 1:13:52 PM
From: Jibacoa	Respond to of 3722

ANDS Has formed a base at the 3.15 level & seems that it will close some of its June 26 downgap. bigcharts.marketwatch.com Apparently the appointment of Dr. Freddo as CMO has been well received. June 26 was the day when it suspended dosing HCV patients on its P1b of ANA975 pending further evaluation of data from toxicology studies in animals. They believe that ANA975 "still has potential", & of course, they still have ANA773; ANA380 (which is in PII for HBV); AN 025-1(for HCV); AN 033-1 as well as other products including some that by inhibiting ribosomal function may be used as antibiotics to fight nosocomial infections. ANDS reportedly has low LTD & more than $3 in csh/shr. Since the revenues have shown a triple digits % improvement for 4 consecutive Qs & it has been trimming its loss, it seems that the R/R is low at present levels, especially since the stock presently trading at $4.08 is down substantially from its March H at $16.60. (The intraday H at 12.56 was $4.25 <g>) bigcharts.marketwatch.com Disclosure: I don't have a position on ANDS at present. (Have considered starting one, but don't like the triple digits drops on the DOW.<g>) bigcharts.marketwatch.com Bernard